NREP
NEW REPRESENTATIVE AT IB RECEIVED
12/03/2026
Voltar para busca
Dado oficial do USPTO
LCA PHARMACEUTICAL
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
37
Atualização mais recente
13/03/2026
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5, 10, 42, 44
Data de depósito
07/10/2016
Data de registro
13/03/2018
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
27/09/2024
Última transação
13/03/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
709
Cadastro oficial
Principal Register
Código do desenho
3
Tipo de titular
33
Localização do titular
FR
Examinador
TWOHIG, SHANNON MARIE
Unidade examinadora
N30
Localização atual
TMO LAW OFFICE 121
Descrição da marca
The mark consists of the stylized letters "LCA" in white above the stylized word "PHARMACEUTICAL" in white. The wording appears superimposed over a blue background and blue globe design.
Titulares e representantes
Titulares
LABORATOIRE DE CONTACTOLOGIE APPLIQUEE - LCA,
Representantes
Leigh Ann Lindquist Sughrue Mion, PLLC
Classificação técnica
Classes Nice
Classe 5Classe 10Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical productspreparations for the treatment of osteoarthritis and other joint diseases; preparations for the treatment of pain and joint diseasesparticularly osteoarthritis; injectable preparations for use in rheumatologypresented in the form of pre-filled disposable sterile syringes; preparations for dermatological use for filling in face wrinkles; pharmaceutical preparations for dermatological use; injectable preparations for dermatological use presented in the form of sterile pre-filled disposable syringes; Sterileisotonic and preservative-free single doses for symptomatic treatments of eye irritations and for nose and eye care
Classe 10
Surgical and medical apparatus and instrumentssterile single use instrumentation for cataract surgery; Medical devices for intracorporal injectionlenses in the nature of intraocular prostheses for surgical implantation packed in an injector; medical devices for intracorporeal injection; medical devices for intracorporeal injection consisting of a disposable sterile syringe; artificial implantsnamely introcular implants; sterile intraocular implants of artificial material and medical devices for use in cataract surgery
Classe 42
Pharmaceutical research services; medical research services; scientific data analysis services; chemical analyses; chemical research; medical data analysis services; scientific research services for medical purposesparticularly design and development of implantable medical devices for use in ophthalmologyrheumatology and dermatology
Classe 44
Medical services; medical assistance; health counseling services; pharmacy advicemedical advice related to pharmaceuticals; health care for human beings; advisory services and medical services in the field of rheumatology and dermatology; hygiene and beauty care; all the aforementioned services not in the field of ophthalmology
Publicações
Histórico de despachos e eventos da marca no USPTO.
37 publicações encontradas
INNT
TOTAL INVALIDATION PROCESSED BY THE IB
24/10/2025
XXSS
GENERIC MADRID TRANSACTION SENT TO IB
02/10/2025
XXCR
GENERIC MADRID TRANSACTION CREATED
02/10/2025
INTR
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
27/05/2025
C71T
CANCELLED SECTION 71
27/09/2024
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
13/03/2023
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
24/08/2018
XXSS
GENERIC MADRID TRANSACTION SENT TO IB
20/06/2018
XXCR
GENERIC MADRID TRANSACTION CREATED
20/06/2018
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
13/06/2018
R.PR
REGISTERED-PRINCIPAL REGISTER
13/03/2018
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
26/12/2017
PUBO
PUBLISHED FOR OPPOSITION
26/12/2017
GPNX
NOTIFICATION PROCESSED BY IB
22/12/2017
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
06/12/2017
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
06/12/2017
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
06/12/2017
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
14/11/2017
XAEC
EXAMINER'S AMENDMENT ENTERED
14/11/2017
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
14/11/2017
GNEA
EXAMINERS AMENDMENT E-MAILED
14/11/2017
CNEA
EXAMINERS AMENDMENT -WRITTEN
14/11/2017
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
21/09/2017
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
21/09/2017
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
21/09/2017
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
20/09/2017
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
20/09/2017
RFNT
REFUSAL PROCESSED BY IB
09/04/2017
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
21/03/2017
RFRR
REFUSAL PROCESSED BY MPU
21/03/2017
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
21/03/2017
MAFR
APPLICATION FILING RECEIPT MAILED
21/03/2017
CNRT
NON-FINAL ACTION WRITTEN
20/03/2017
DOCK
ASSIGNED TO EXAMINER
17/03/2017
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
17/03/2017
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
16/03/2017
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace LCA PHARMACEUTICAL ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.